Intra-arterial cisplatin for bladder cancer

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Locally advanced bladder cancer requires effective treatment strategies.
• Intra-arterial chemotherapy offers targeted delivery for localized disease.

Purpose of the Study:

• To evaluate the efficacy and toxicity of intra-arterial cisplatin in patients with locally advanced bladder cancer.
• To determine optimal dosing and identify patient factors influencing response and toxicity.

Main Methods:

• 33 patients with locally advanced bladder cancer received intra-arterial cisplatin (25-120 mg/m²).
• Response was assessed by cystoscopy and clinical evaluation.
• Toxicity was monitored and graded.

Main Results:

• Of 21 evaluable patients, 14% achieved complete remission and 57% partial remission.
• Higher doses (100-120 mg/m²) showed a higher response rate (86%) compared to lower doses (64%).
• Dose-related neurotoxicity was observed, especially at higher doses, with diabetic patients being more susceptible.

Conclusions:

• Intra-arterial cisplatin is an effective treatment for locally advanced bladder cancer, particularly at higher doses.
• Careful dose selection and patient monitoring are crucial to manage toxicity.
• Further studies with optimized dosing are warranted.